Reuters logo
8 months ago
BRIEF-Pharnext presents positive exploratory Phase 2 data from clinical trials on Alzheimer
December 13, 2016 / 7:27 AM / 8 months ago

BRIEF-Pharnext presents positive exploratory Phase 2 data from clinical trials on Alzheimer

Dec 13 (Reuters) - Pharnext SAS :

* Presents positive exploratory Phase 2 data from PXT864 at 9th clinical trials on Alzheimer's disease (CTAD) conference in San Diego, United States

* Trial also confirmed excellent safety and tolerability of PXT864 over 36 weeks of treatment

* Data from Phase 2 trial suggest promising efficacy of PXT864 in mild Alzheimer`s disease Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below